Abstract:Objective:QL0911, a recombinant human thrombopoietin mimetic peptide-Fc fusion protein, is a romiplostim (Nplate®) biosimilar used to treat primary immune thrombocytopenia (ITP). This phase III study aimed to assess the efficacy and safety of QL0911 in adult patients with chronic primary ITP over a 24-week treatment period. Methods:We conducted a double-blind, placebo-controlled, phase III study in patients diagnosed with primary ITP for at least 12 months who had received at least one first-line ITP treatment with no response or recurrence after treatment, or who relapsed after splenectomy at 44 sites in China. Patients were randomly allocated (2:1 ratio) to QL0911 or placebo injection subcutaneously once weekly at an initial dose of 1 μg/kg for 24 weeks. The doses were adjusted to maintain the target platelet counts from 50 × 109/L to 200 × 109/L. Patients and investigators were blinded to the assignment. The primary endpoints were the proportion of patients who achieved a durable platelet response at week 24 (platelet count, ≥ 50 × 109/L during 6 of the last 8 weeks of treatment) and safety. The study was registered at ClinicalTrials.gov (NCT05621330). Results:Between October 2019 and December 2021, 216 patients were randomly assigned (QL0911,144; placebo,72). A durable platelet response was achieved by significantly more patients in the QL0911 group (61.8%, 95% CI: 53.3-69.8; P < 0.0001) than in the placebo group (0%). The mean duration of platelet responses was 15.9 (SE: 0.43) weeks with QL0911, and 1.9 (SE:0.26) week with placebo. Consistent results were achieved in subgroup analyses categorized by baseline splenectomy status (yes/no), concomitant ITP treatment (yes/no), and baseline platelet count (≤ 10 × 109/L, > 10 × 109/L, ≤ 20 × 109/L, > 20 × 109/L, and < 30 × 109/L). The incidence of TEAEs was comparable between the QL0911 and the placebo groups (91.7% and 88.9%, respectively). The most common adverse events overall were ecchymosis (28.5% for QL0911 vs. 37.5% for placebo), upper respiratory tract infections respiratory tract infections (31.9% for QL0911 vs. 27.8% for placebo), and gingival bleeding (17.4% for QL0911 vs. 26.4% for placebo). Conclusion:QL0911 was well-tolerated and increased and maintained platelet counts in adults with ITP. QL0911, a biosimilar to romiplostim (Nplate®), may be a novel treatment option for patients with ITP who have failed or relapsed from first-line treatment in China. Ongoing studies will provide further data on long-term efficacy and safety in such patient populations.

[A Multi-Center Clinical Trial of Recombinant Human Thrombopoietin in Chronic Refractory Idiopathic Thrombocytopenic Purpura].

A Novel Recombinant Human Thrombopoietin for Treating Prolonged Isolated Thrombocytopenia after Allogeneic Stem Cell Transplantation.

A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia

Efficacy and Safety of QL0911 in Adult Patients with Chronic Primary Immune Thrombocytopenia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.

Clinical Analysis of Recombinant Human Thrombopoietin for Treatment of 46 Adult Patients with Newly Diagnosed Primary Immune Thrombocytopenia]

Multiple cycles of recombinant human thrombopoietin therapy in a patient with chronic refractory idiopathic thrombocytopenic purpura

Romiplostim in Primary Immune Thrombocytopenia That is Persistent or Chronic: Phase III Multicenter, Randomized, Placebo-Controlled Clinical Trial in China

Evidence-based Evaluation of Recombinant Human Thromobopoietin for Refractory Idiopathic Thrombocytopenic Purpura

A prospective study of the efficacy and safety of maintenance therapy with recombinant human thrombopoietin in patients with primary immune thrombocytopenia: a multicenter study

Development of Recombinant Human Thrombopoietin Antibodies Following Multi -Dosing, Subcutaneously Medication in Thrombocytopenic Patients

[A clinical comparative study on treatment of severe newly diagnosed immune thrombocytopenia by recombinant human thrombopoietin combined with glucocorticoid].

Efficacy and safety of recombinant human thrombopoietin for the treatment of chronic primary immune thrombocytopenia in children and adolescents: A multicentre, randomized, double‐blind, placebo‐controlled phase III trial

Meta-analysis of Recombinant Human Thromobopoietin in the Treatment of Hematology Malignance Chemotherapy Induced Thrombocytopenia

Clinical Observation Study of Recombinant Human Thrombopoietin in the Prevention of Chemotherapy-Induced Thrombocytopenia in Patients with Aggressive Lymphoma.

Clinical Study of Recombinant Human Thrombopoietin in Patients with Sepsis-Associated Thrombocytopenia

Recombinant Human Thrombopoietin Improves Platelet Recovery after Allogeneic Hematopoietic Stem Cell Transplantation: A Randomized, Controlled Clinical Trial

Safety and efficacy of hetrombopag in patients with chronic immune thrombocytopenia: a single-arm, open-label, multi-center phase 1 study

Recombinant Human Thrombopoietin Accelerates the Recovery of Platelet in Patients With Lower-Risk Myelodysplastic Syndrome: A Proof-of-Concept Study

Recombinant Thrombopoietin Effectively Shortens the Time to Response and Increases Platelet Counts in Elderly Patients with Severe Immune Thrombocytopenia

Long-term remission induced by low-dose rituximab for relapsed and refractory thrombotic thrombocytopenic purpura: A report of two cases.

Combination therapy with recombinant human thrombopoietin and low-dose rituximab for corticosteroid-resistant/relapsed adult ITP:a multicenter clinical trial